Abstract：
OBJECTIVE: Contradictory results have been reported about hyperintensity of the globus pallidus and/or dentate nucleus on unenhanced T1-weighted magnetic resonance (MR) images after exposure to various gadolinium-based contrast agents. This change in signal intensity varies with different gadolinium-based contrast agents. We aimed to determine whether signal intensity in the dentate nucleus is increased in unenhanced T1-weighted images in patients who have undergone multiple studies with the macrocyclic gadolinium-based contrast agent gadoterate meglumine. We thoroughly reviewed the literature to corroborate our results.
METHODS: We included patients who had undergone more than 10 MR studies with gadoterate meglumine. We quantitatively analyzed the signal intensity in unenhanced T1-weighted MR images measured in regions of interest placed in the dentate nucleus and the pons, and we calculated the dentate nucleus-to-pons signal intensity ratios and the differences between the ratio in the first MR study and the last MR study. We used t-tests to evaluate whether the differences between the signal intensity ratios were different from 0. We also analyzed the subgroups of patients who had been administered <15 and ≥15 doses of gadoterate meglumine. We used Pearson correlation to determine the relationships between the differences in the signal intensity ratios and the number of doses of gadoterate meglumine administered.
RESULTS: The 54 patients (26 men) had received a mean of 13.8±3.47 doses (range, 10-23 doses). The difference in the dentate nucleus-pons signal intensity ratio between the first and last MR study was -0.0275±0.1917 (not significantly different from 0; p=0.2968) in the entire group, -0.0357±0.2204 (not significantly different from 0; p = 0.351 in the patients who had received <15 doses (n=34), and -0.0135±0.1332 (not significantly different from 0; p = 0.655) in those who had received ≥15 doses (n=20). Differences in signal intensity ratios did not correlate significantly with the accumulated dose of gadoterate meglumine (P = 0.9064; ρ = -0.0164 [95%]).
CONCLUSIONS: Receiving more than 10 doses of gadoterate meglumine was not associated with increased signal intensity in the dentate nucleus.
METHODS: We included patients who had undergone more than 10 MR studies with gadoterate meglumine. We quantitatively analyzed the signal intensity in unenhanced T1-weighted MR images measured in regions of interest placed in the dentate nucleus and the pons, and we calculated the dentate nucleus-to-pons signal intensity ratios and the differences between the ratio in the first MR study and the last MR study. We used t-tests to evaluate whether the differences between the signal intensity ratios were different from 0. We also analyzed the subgroups of patients who had been administered <15 and ≥15 doses of gadoterate meglumine. We used Pearson correlation to determine the relationships between the differences in the signal intensity ratios and the number of doses of gadoterate meglumine administered.
RESULTS: The 54 patients (26 men) had received a mean of 13.8±3.47 doses (range, 10-23 doses). The difference in the dentate nucleus-pons signal intensity ratio between the first and last MR study was -0.0275±0.1917 (not significantly different from 0; p=0.2968) in the entire group, -0.0357±0.2204 (not significantly different from 0; p = 0.351 in the patients who had received <15 doses (n=34), and -0.0135±0.1332 (not significantly different from 0; p = 0.655) in those who had received ≥15 doses (n=20). Differences in signal intensity ratios did not correlate significantly with the accumulated dose of gadoterate meglumine (P = 0.9064; ρ = -0.0164 [95%]).
CONCLUSIONS: Receiving more than 10 doses of gadoterate meglumine was not associated with increased signal intensity in the dentate nucleus.
摘要：
目的：关于苍白球和/或齿状核暴露于各种基于钆的造影剂后，在未增强的T1加权磁共振（MR）图像上，有矛盾的结果。信号强度的这种变化随不同的基于钆的造影剂而变化。我们的目的是确定在接受了基于大环钆的造影剂gadoterate葡甲胺的多项研究的患者中，在未增强的T1加权图像中，齿状核中的信号强度是否增加。我们彻底回顾了文献以证实我们的结果。
方法：我们纳入了接受过10次以上加多酯葡甲胺MR研究的患者。我们定量分析了在位于齿状核和脑桥中的感兴趣区域中测量的未增强的T1加权MR图像中的信号强度，我们计算了第一次MR研究和最后一次MR研究中齿状核与桥的信号强度比以及该比值之间的差异。我们使用t检验来评估信号强度比之间的差异是否不同于0。我们还分析了服用<15和≥15剂量的加多酯葡甲胺的患者亚组。我们使用Pearson相关性来确定信号强度比率的差异与施用的gadoterate葡甲胺的剂量数之间的关系。
结果：54名患者（26名男性）平均接受了13.8±3.47次剂量（范围，10-23剂）。在整个组中，第一次和最后一次MR研究之间的齿状核-桥脑信号强度比差异为-0.0275±0.1917（与0无显着差异；p=0.2968），-0.0357±0.2204（与0无显着差异；在接受<15剂（n=34）的患者中，p=0.351，和-0.0135±0.1332（与0无显着差异；p=0.655）在那些接受≥15剂量（n=20）的人中。信号强度比的差异与gadoterate葡甲胺的累积剂量没有显着相关（P=0.9064；ρ=-0.0164[95％]）。
结论：接受超过10剂量的加多酯葡甲胺与齿状核的信号强度增加无关。
方法：我们纳入了接受过10次以上加多酯葡甲胺MR研究的患者。我们定量分析了在位于齿状核和脑桥中的感兴趣区域中测量的未增强的T1加权MR图像中的信号强度，我们计算了第一次MR研究和最后一次MR研究中齿状核与桥的信号强度比以及该比值之间的差异。我们使用t检验来评估信号强度比之间的差异是否不同于0。我们还分析了服用<15和≥15剂量的加多酯葡甲胺的患者亚组。我们使用Pearson相关性来确定信号强度比率的差异与施用的gadoterate葡甲胺的剂量数之间的关系。
结果：54名患者（26名男性）平均接受了13.8±3.47次剂量（范围，10-23剂）。在整个组中，第一次和最后一次MR研究之间的齿状核-桥脑信号强度比差异为-0.0275±0.1917（与0无显着差异；p=0.2968），-0.0357±0.2204（与0无显着差异；在接受<15剂（n=34）的患者中，p=0.351，和-0.0135±0.1332（与0无显着差异；p=0.655）在那些接受≥15剂量（n=20）的人中。信号强度比的差异与gadoterate葡甲胺的累积剂量没有显着相关（P=0.9064；ρ=-0.0164[95％]）。
结论：接受超过10剂量的加多酯葡甲胺与齿状核的信号强度增加无关。
